Survey of 80 insurers globally examines investment portfolio positioning plans for 2024.

Insurers and sponsors tasked with funding new drugs or limiting their usage.

Second highest quarter-over-quarter growth rate reported since 2016.

New drug impacts on private drug plans examined in new report.

Downward trajectory continues following peak pandemic years

Highest sales ever recorded in the Canadian market since the LIMRA survey was established.

The insurer calls the transaction the largest of its kind in Canada.